AOS-1 Inhibitors
Chemical inhibitors of AOS-1 can have a significant impact on its sumoylation activity by altering various cellular processes and pathways. MLN4924 (Pevonedistat) inhibits the NEDD8-activating enzyme, which is important for the neddylation process. While this does not directly target AOS-1, disrupting neddylation can have downstream effects on the sumoylation process, potentially resulting in the functional inhibition of AOS-1. Similarly, proteasome inhibitors such as Bortezomib, MG132, and Ixazomib lead to the accumulation of proteins within the cell. This accumulation can indirectly inhibit AOS-1 by causing a backlog of sumoylation substrates, thereby overwhelming the sumoylation system and compromising AOS-1's activity.
Anacardic Acid and Ginkgolic Acid, both histone acetyltransferase inhibitors, may indirectly affect AOS-1 by changing the availability of sumoylation substrates due to altered chromatin structure. Chloroquine's ability to raise endosomal pH affects the cellular trafficking of proteins, potentially causing a mislocalization of substrates or components of the sumoylation machinery, which could hinder AOS-1's function. Curcumin may affect AOS-1 by modifying the substrate interaction or localization of SUMO proteins. Arsenic Trioxide can lead to the degradation of proteins involved in nuclear body formation, which are essential for sumoylation, thereby affecting AOS-1's activity. Betulinic Acid promotes the cleavage of SUMO from its substrates, reducing the available SUMO for AOS-1-mediated sumoylation. NSC 697923 targets Ubc9, a SUMO-conjugating enzyme, and by inhibiting it, the conjugation of SUMO to target proteins is prevented, which indirectly inhibits the sumoylation process that involves AOS-1. Tenovin-6, a SIRT1 inhibitor, can alter the cellular acetylation status, which, due to the interconnection between acetylation and sumoylation, could influence AOS-1 activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $286.00 | 1 | |
MLN4924 inhibits the NEDD8-activating enzyme (NAE) which is essential for the neddylation process. Since AOS-1 is a part of the SUMO-activating enzyme complex necessary for sumoylation, the inhibition of neddylation can indirectly affect sumoylation processes by disrupting the overall post-translational modification environment within the cell, potentially inhibiting AOS-1 indirectly. | ||||||
Anacardic Acid | 16611-84-0 | sc-202463 sc-202463A | 5 mg 25 mg | $102.00 $204.00 | 13 | |
Anacardic Acid inhibits histone acetyltransferases (HATs). Although this does not directly affect AOS-1, the resulting alterations in chromatin structure can indirectly inhibit the sumoylation process by affecting the substrate availability for AOS-1. | ||||||
Ginkgolic acid C15:1 | 22910-60-7 | sc-235249 | 5 mg | $312.00 | 2 | |
Ginkgolic Acid is also a HAT inhibitor with a mechanism similar to Anacardic Acid, potentially leading to indirect inhibition of AOS-1 by altering substrate availability for sumoylation due to changes in chromatin structure. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Chloroquine raises endosomal pH, which can disrupt the cellular trafficking of proteins. This may indirectly affect AOS-1 by impeding the transport and localization of substrates or components of the sumoylation machinery, thereby functionally inhibiting AOS-1. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib inhibits the 26S proteasome, leading to the accumulation of proteins that might have been degraded. This could indirectly affect AOS-1 by causing a backlog of proteins that require sumoylation, effectively overloading the system and inhibiting AOS-1's function due to a lack of capacity. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 is a proteasome inhibitor similar to Bortezomib. It can indirectly inhibit AOS-1 by causing an accumulation of sumoylated proteins that should be degraded, thereby potentially disrupting the dynamics of the sumoylation process and indirectly inhibiting AOS-1. | ||||||
Ixazomib | 1072833-77-2 | sc-489103 sc-489103A | 10 mg 50 mg | $311.00 $719.00 | ||
Ixazomib is another proteasome inhibitor that could lead to an indirect functional inhibition of AOS-1 by causing an accumulation of proteins that would otherwise be degraded, potentially disrupting the sumoylation cycle. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $37.00 $69.00 $109.00 $218.00 $239.00 $879.00 $1968.00 | 47 | |
Curcumin has been shown to inhibit the activity of various enzymes. It may indirectly affect AOS-1's sumoylation activity by modifying the interaction between AOS-1 and its substrates or by altering the intracellular localization of SUMO proteins. | ||||||
Arsenic(III) oxide | 1327-53-3 | sc-210837 sc-210837A | 250 g 1 kg | $89.00 $228.00 | ||
Arsenic Trioxide can lead to the degradation of PML, a protein involved in the formation of nuclear bodies where sumoylation occurs. This could indirectly inhibit AOS-1 by disrupting the nuclear architecture needed for efficient sumoylation. | ||||||
Betulinic Acid | 472-15-1 | sc-200132 sc-200132A | 25 mg 100 mg | $117.00 $344.00 | 3 | |
Betulinic Acid can induce the cleavage of SUMO from its conjugated substrates. By promoting de-sumoylation, it could indirectly inhibit AOS-1 by reducing the pool of SUMO available for AOS-1's sumoylation activity. | ||||||